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Background: Radioresistance is the main limit to the efficacy of radiotherapy in nasopharyngeal carcinoma (NPC).
SHP-1 is involved in cancer progression, but its role in radioresistance and senescence of NPC is not well
understood. This study aimed to assess the role of SHP-1 in the radioresistance and senescence of NPC cells.
Methods: SHP-1 was knocked-down and overexpressed in CNE-1 and CNE-2 cells using lentiviruses. Cells were
irradiated to observe their radiosensitivity by colony forming assay. BrdU incorporation assay and flow cytometry
were used to monitor cell cycle. A β-galactosidase assay was used to assess senescence. Western blot was used to
assess SHP-1, p21, p53, pRb, Rb, H3K9Me3, HP1γ, CDK4, cyclin D1, cyclin E, and p16 protein expressions.
Results: Compared with CNE-1-scramble shRNA cells, SHP-1 downregulation resulted in increased senescence
(+107 %, P < 0.001), increased radiosensitivity, higher proportion of cells in G0/G1 (+33 %, P < 0.001), decreased
expressions of CDK4 (−44 %, P < 0.001), cyclin D1 (−41 %, P = 0.001), cyclin E (−97 %, P < 0.001), Rb (−79 %, P < 0.001),
and pRb (−76 %, P = 0.001), and increased expression of p16 (+120 %, P = 0.02). Furthermore, SHP-1 overexpression
resulted in radioresistance, inhibition of cellular senescence, and cell cycle arrest in the S phase. Levels of p53 and
p21 were unchanged in both cell lines (all P > 0.05).
Conclusion: SHP-1 has a critical role in radioresistance, cell cycle progression, and senescence of NPC cells.
Down-regulating SHP-1 may be a promising therapeutic approach for treating patients with NPC.
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Nasopharyngeal carcinoma (NPC) is a cancer with a dis-
tinctly skewed geographic and ethnic distribution, and is
endemic in Southern China and South East Asia [1]. In-
deed, type I NPC represents 25 % of the cases in North
America and 2 % in Southern China, while type III repre-
sents 95 % of the cases in China and 63 % in North Amer-
ica [1]. NPC mostly affects men (men:women ratio of
4.4:1), and the median age at diagnosis is in the early 60s.
Worldwide incidence is <1 per 100,000 for either men or
women, but the incidence is 20–30 per 100,000 in Hong* Correspondence: penggangsci@sina.com
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creativecommons.org/publicdomain/zero/1.0/Kong and 15–20 per 100,000 in Guangdong [1]. Tobacco
and alcohol are the two main risk factors for NPC [2–4].
Human papillomavirus and Epstein-Barr virus also increase
the risk of NPC, particularly in endemic regions [5, 6].
Mean survival of patients with stage I, II, or III NPC is
about 3 years [7].
Radiotherapy (RT) is the main treatment for NPC since
radical resection is typically not possible [4]. The advent of
megavoltage radiotherapy has transformed a once lethal
cancer into one that is readily curable. Non-keratinizing un-
differentiated carcinoma (type III NPC) is the most com-
mon of the three forms of NPC, and is sensitive to
radiations [4]. Overall survival exceeding 50 % at five years
may now be achieved [8, 9].le distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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benefits from radiotherapy [10]. The mechanisms of radio-
resistance are mostly unknown. Recent studies using mi-
croarrays have explored the genes involved in the
radioresistance of solid tumors such as cervix, pancreas,
mouth, lung, and esophagus and failed to identify common
genes [11]. Nevertheless, recent studies have shown that a
number of proteins involved in the cell cycle (gp96,
GDF15, PTEN) were involved in the radioresistance of
NPC [11, 12].
SHP-1 (initially designated as SHPTP-1, SHP, HCP, and
PTPIC) is a cytosolic protein tyrosine phosphatase
expressed primarily in hematopoietic cells [13]. SHP-1 has
been proposed as a candidate tumor suppressor gene in
lymphoma and solid cancers [14]. SHP-1 can play either
negative or positive roles in regulating signal transduction
pathways and is differentially expressed in a number of can-
cer cell lines [14–16]. Therefore, SHP-1 appears to have dif-
ferent roles and mechanisms in the regulation of cell cycle
and cell proliferation in different types of tumors.
Recent data validated the early idea that cellular senes-
cence is important for tumor suppression [17, 18]. Cellular
senescence is a barrier to tumorigenesis and contributes to
mammalian aging [19]. Furthermore, cellular senescence
depends critically on two powerful tumor suppressor
pathways: the p53 and pRb/p16INK4a pathways. These
pathways are known to regulate cellular senescence/im-
mortalization including the p16INK4a/pRB, p19ARF/p53/
p21CIP1/WAF1, and PTEN/p27KIP1 pathways [20–22].
A previous study has shown that SHP-1 knockdown re-
sulted in a G1/S arrest and an increase in the expression
of p16 [23]. This previous study investigated the associ-
ation between SHP-1 and p16, since p16 has previously
been demonstrated to be silenced in the vast majority of
NPCs [24], which suggested that SHP-1 may regulate cel-
lular senescence through the p16 pathway.
Therefore, the aim of the present study was to study
the association between expression of SHP-1 and cellular
senescence, radioresistance and cell cycle distribution in
NPC cells. This study is the first to propose that SHP-1
regulates a senescence response.
Methods
Cell culture
The human NPC cell lines CNE-1 and CNE-2 were ob-
tained from the Cell Bank of Sun Yat-sen University
(Guangzhou, China), and cultured in RPMI 1640 (Invi-
trogen Inc., Carlsbad, CA, USA) supplemented with
10 % fetal bovine serum (FBS, Invitrogen Inc., Carlsbad,
CA, USA) and 1 % penicillin/streptomycin (Invitrogen
Inc., Carlsbad, CA, USA). Cells were kept at 37 °C in
5 % CO2 atmosphere. The CNE-1 cell line was estab-
lished in 1978 from a patient with NPC [25], and the
CNE-2 cell line was established in 1983 from a poorlydifferentiated NPC [26]. The CNE-2 cell line has been
shown to be less radio-resistant than CNE-1 [27], and
the DNA repair mechanisms seem to be more efficient
in the CNE-1 cell line [27, 28].
SHP-1 overexpression and knockdown mediated
by lentiviruses
For SHP-1 knockdown, cells were plated in 24-well plates
and cultured with 0.5 ml of RPMI 1640 supplemented with
5 % FBS and 1 % penicillin/streptomycin for 24 h. Cells
were then transduced with 50 μl (8.6 × 109 copies/ml)
of lentivirus-mediated SHP-1-shRNA vector (lot: LP-
HSH015860-LVRH1MP) and scramble shRNA vector (lot:
LP-CSHCTR001-LVRH1MP) (GeneCopoeia, Guangzhou,
China) for 48 h. These vectors contained a puromycin re-
sistance gene for the selection of transduced cells. Then,
the transduced cells were digested with trypsin, plated in
6-well plates, and cultured in RPMI 1640 supplemented
with 10 % FBS, 1 % penicillin/streptomycin and 2 μg/ml of
puromycin for 12 days to screen for stably transduced
cells. The medium containing puromycin was changed
every three days. Puromycin-resistant clones were se-
lected. SHP-1 mRNA and protein expressions were deter-
mined by real-time RT-PCR and western blot.
For SHP-1 overexpression, cells were plated in 24-well
plates and cultured with 0.5 ml of RPMI 1640 supple-
mented with 15 % FBS and 1 % penicillin/streptomycin for
24 h. Cells were then transduced with 50 μl (8.6 × 109 cop-
ies/ml) of lentivirus-mediated SHP-1-overexpression vector
(lot: LP-H1802-Lv201-C0010) and scramble shRNA vector
(lot: LP-NEG-Lv201-0200) (GeneCopoeia, Guangzhou,
China) for 48 h. These vectors contained a puromycin re-
sistance gene for the selection of transduced cells. Then,
the transduced cells were observed using a Zeiss Axioplan
2 fluorescence microscope (Carl Zeiss GmbH, Oberkochen,
Germany) equipped with a Plan Neofluar 20x/0.5 objective,
color camera Infinity X and Deltapix software (DeltaPix,
Nibe, Denmark). Transduced cells were digested with tryp-
sin, plated in 6-well plates, and cultured in RPMI 1640 sup-
plemented with 15 % FBS, 1 % penicillin streptomycin and
2 μg/ml of puromycin for 12 days to screen for stably trans-
duced cells. The medium containing puromycin was chan-
ged every three days. Puromycin-resistant clones were
selected. SHP-1 mRNA and protein expressions were deter-
mined by real-time RT-PCR and western blot.
Colony forming assay
Cells were seeded in 6-well culture plates at different cell
densities (200, 300, 600, 1500, and 4000 cells/well) and
irradiated the next day using different doses (0, 2, 4, 6,
and 8 Gy). The plates were incubated for 14 days, fixed
with methanol, and stained with Giemsa (Sigma, St
Louis, MI, USA). Colonies containing at least 50 cells
were counted as a clone. A multi-target single-hit model
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equation SF = 1-(1-e-D/D0)N, where SF is the cell survival
fraction, D is the radiation dose, e is the natural loga-
rithm, D0 is the mean lethal dose, and N is the extrapo-
lated number. Survival curves were made using these SF.
BrdU incorporation assay
Cells were cultured on glass slides and were incubated
with 10 μM BrdU (Sigma, St Louis, MI, USA) for 6 h be-
fore fixation with 4 % formaldehyde. After DNA de-
naturation in 2 M HCl for 30 min, cells were washed in
PBS and incubated with mouse anti-human primary
antibody against BrdU (RPN20AB, 1:300, AP-Biotech
S.R.L., Buenos Aires, Argentica). The secondary antibody
Alexa Fluor® 568 goat anti-mouse (#A110-31, 1:500,
Invitrogen Inc., Carlsbad, CA, USA) was then applied
for 60 min at room temperature, followed by a final
wash in PBS. Glass slides were mounted in Vectashield
Mounting Medium with HOCHEST (Vector Laborator-
ies, Burlingame, CA, USA). Images were acquired using
an AxioObserver fluorescence microscope (Carl Zeiss
GmbH, Oberkochen, Germany) equipped with a Plan
Apochromat 20x/0.8 objective, camera Coolsnap HQ
(Photometrics, Tucson, AZ, USA) and the Metamorph
software (Universal Imaging, Bedford Hills, NY, USA).
Two independent observers blinded to grouping counted
the BrdU-positive cells in 35 random fields (approxi-
mately 500 cells) for each glass slide, and the percentage
of BrdU-positive cells was calculated. Data analysis was
performed using ImageJ 1.43u (National Institutes of
Health, Bethesda, MD, USA).
Senescence-associated β-galactosidase
Staining for senescence-associated-β-galactosidase activity
was performed using a Senescence β-Galactosidase Staining
Kit (#9860, Cell Signaling, Danvers, MA, USA) according
to the manufacturer’s protocol. β-galactosidase positive cells
(green) were viewed by light microscopy.
Immunofluorescence
For immunofluorescence, cells were cultured on glass
slides, fixed in 4 % formaldehyde and permeabilized by
0.1 % Triton X-100 in two consecutive steps, each for
15 min at room temperature. After washing with PBS,
cells were blocked for 30 min in 10 % fetal calf serum.
The following primary antibodies were used: rabbit anti-
human polyclonal antibody against histone H3 trimethy-
lated at lysine 9 (H3K9Me3, #07-442, 1:1,000, Millipore
corp., Billerica, MA, USA) and mouse anti-human poly-
clonal antibody against heterochromatin protein-1γ
(HP1γ, #MAB3450, 1:4,000, Millipore corp., Billerica,
MA, USA). Incubation with the primary antibodies was
performed for 60 min at room temperature and the cells
were washed with PBS. The secondary antibodies AlexaFluor® 568 goat anti-mouse (#A110-31, 1:500, Invitrogen
Inc., Carlsbad, CA, USA) and Alexa Fluor® 488 goat anti-
rabbit (#A-11008, 1:500, Invitrogen Inc., Carlsbad, CA,
USA) were then applied for 60 min at room temperature,
followed by a final wash in PBS. Glass slides were mounted
in Vectashield Mounting Medium with HOCHEST (Vec-
tor Laboratories, Burlingame, CA, USA). Confocal images
were acquired using a LSM-510 microscope (Carl Zeiss
GmbH, Oberkochen, Germany) equipped with a Plan-
Apochromat 63x/1.4 oil immersion objective and the
ZEN2009 software (Carl Zeiss GmbH, Oberkochen,
Germany). Identical image acquisition parameters were
used for quantitative and comparative imaging. Percentage
of senescence-associated heterochromatin foci (SAHF)-
positive cells (based on Hoechst staining) and numbers of
H3K9Me3 and HP1γ foci per cell were counted by two in-
dependent observers blinded to grouping from at least 200
cells from each glass slide. Data analysis was performed
using ImageJ 1.43u (National Institutes of Health,
Bethesda, MD, USA).
Flow cytometry
After transduction with the indicated lentiviruses, cells
were fixed overnight with 70 % ethanol, followed by re-
suspension in PBS containing 1 mg/ml of RNase and
50 μg/ml of propidium iodide (Sigma, St Louis, MI,
USA). Cellular DNA content was determined using a
FACScan flow cytometer (BD Biosciences, Franklin Lake,
NJ, USA).
Real-time RT-PCR
Total RNA was extracted using TRIzol (Invitrogen, NM,
USA), and cDNA synthesis was performed using the
Prime Script RT-PCR kit (Takara, Shiga, Japan), accord-
ing to the manufacturers’ instructions. Then, real-time
PCR was performed using SYBR Green PCR Master Mix
(Applied Biosystems, USA) in a PCR amplifier (ABI Prism
7000, USA). The StepOneTM Software v2.1 was used to
analyze the data. The primer sequences for SHP-1 were:
Forward, 5’-ACCATCATCCACCTCAAGTACC-3’ and
Reverse, 5’-CTGAGCACAGAAAGCACGAA-3’. β-actin
was used as an internal control, and the primer sequences
were: Forward, 5’-GATGAGATTGGCATGGCTTT-3’ and
Reverse, 5’-CACCTTCACCGTTCCAGTTT-3’. 2-ΔΔCt
was calculated to represent the relative mRNA expression
of target genes.
Western blot
Cells were lysed with the RIPA buffer (Invitrogen Inc.,
Carlsbad, CA, USA), and then centrifuged (12,000 rpm,
15 min, 4 °C). Protein content was measured using a BCA
assay. Equal amounts of proteins (20–80 μg) were separated
with 10 % sodium docecyl sulfate-polyacrylamide gel elec-
trophoresis, and transferred to polyvinylidene difluoride
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USA). Membranes were blocked with 5 % BSA for 1 h, and
probed using mouse anti-human p21 (1:400; Abcam, Cam-
bridge, MA, USA), mouse anti-human p53 (1:1000, Cell
Signaling, Danvers, MA, USA), mouse anti-human pRb
(Ser795) (1:1000, Cell Signaling, Danvers, MA, USA),
mouse anti-human Rb (1:2000, Cell Signaling, Danvers,
MA, USA), mouse anti-human H3K9Me3 (1:500, Millipore
corp., Billerica, MA, USA), mouse anti-humanHP1-γ
(1:500, Millipore corp., Billerica, MA, USA), mouse anti-
human SHP1 (1:1000, Epitomic, San Francisco, CA, USA),
mouse anti-human CDK4 (1:1000, Abcam, Cambridge,
MA, USA), mouse anti-human cyclin D1 (1:1000, Epitomic,
San Francisco, CA, USA), mouse anti-human cyclin E
(1:1000, Bioworld Technology Inc., Louis Park, MN, USA),
mouse anti-human p16 (1:1000, Santa Cruz Biotechnology,
Santa Cruz, CA, USA), or rabbit anti-human β-actin
(1:2500; Sigma, St Louis, MI, USA) polyclonal antibodies
overnight at 4 °C. Primary antibodies were detected using
horseradish peroxidase-conjugated secondary antibodies
(Invitrogen Inc., Carlsbad, CA, USA), and were visualized
using enhanced chemiluminescence (SuperSignal, Pierce,
Rockford, IL, USA). Grayscale images were analyzed using
ImageJ 1.43b (National Institutes of Health, Bethesda,
MD, USA).
Statistical analysis
Statistical analysis was performed using SPSS 12.0 (SPSS
Inc., Chicago, IL, USA). Data are expressed as means ±
standard deviation (SD) of at least three independent ex-
periments and evaluated by one-way analysis of variance
(ANOVA) with the least significant difference (LSD) test
for post hoc analysis or student’s t-test. P-values <0.05
were considered statistically significant.
Results
Expression of SHP-1 by lentivirus-mediated RNA
interference and overexpression
Figure 1a and b show the baseline expression of SHP-1 and
radiosensitivity in CNE-1 and CNE-2 cells. The majority of
cells above 90 % displayed green fluorescence 48 h after
lentivirus transduction (Fig. 1c and d). Real-time RT-PCR
showed that SHP-1 mRNA expression was suppressed by
62.5 % in CNE-1 cells transduced with lentivirus-mediated
SHP-1 shRNA (CNE-1 SHP-1 shRNA), compared with
cells transduced with lentivirus-mediated scramble shRNA
(CNE-1-scramble shRNA), while SHP-1 mRNA expression
was overexpressed 249.2 folds in CNE-2 cells transduced
with lentivirus-mediated SHP-1 overexpression (CNE-2
SHP-1 overexpression), compared with cells transduced
with lentivirus vector (CNE-2-empty vector) (Fig. 1e). Real-
time RT-PCR results were confirmed by western blotting
(Fig. 1f, g, and h), i.e. -47.2 % in CNE-1 SHP-1 shRNA cells,
and +90.3 % in CNE-2 SHP-1 overexpression cells.Effects of SHP-1 knockdown and overexpression in CNE-1
and CNE-2 cells on radiosensitivity
Survival curves of CNE-1, CNE-1-empty vector, CNE-1-
scramble shRNA, CNE-1 SHP-1 shRNA, and CNE-1
SHP-1 overexpression cells after irradiation are shown in
Fig. 2a, and the survival curves of CNE-2, CNE-2-empty
vector, CNE-2-scramble shRNA, CNE-2 SHP-1 shRNA,
and CNE-2 SHP-1 overexpression cells after irradiation
are shown in Fig. 2b. The curves show that SHP-1 over-
expression cells had a higher radioresistance compared
with nontransduced cells or cells transduced with empty
vector (P < 0.001 for all radiation doses) (Fig. 2). Notably,
SHP-1 overexpression cells had higher D0, Dq, and SF2
values compared with non-transduced cells, indicating
higher radioresistance (Table 1). By contrast, D0, Dq,
and SF2 values were similar between the non-transduced
cells and cells transduced with empty vector. On the
other hand, SHP-1 shRNA cells had a lower radioresis-
tance compared with non-transduced cells or cells trans-
duced with scramble shRNA (P < 0.001 for all radiation
doses) (Fig. 2 and Table 1).
Effects of SHP-1 knockdown in CNE-1 cells and
overexpression in CNE-2 cells on NPC cell senescence
Cell cycle arrest is the central feature of senescent cells.
Morphologically, CNE-2 and CNE-2-empty vector cells
were vacuolated, flattened and much larger in size com-
pared with CNE-2 SHP-1 overexpression cells (Fig. 3a).
β-galactosidase staining revealed higher senescence in
CNE-1 SHP-1 shRNA cells compared with CNE-1-
scramble shRNA cells (23.6 ± 3.4 % vs. 11.4 ± 1.8 %, P <
0.001), and lower senescence in CNE-2 SHP-1 overex-
pression cells compared with CNE-2-empty vector cells
(3.6 ± 2.7 % vs. 13.2 ± 3.3 %, P = 0.001) (Fig. 3a).
H3K9Me3 and HP1γ analyses showed that more CNE-1
SHP-1 shRNA cells were positive for H3K9Me3 (13.6 ±
2.7 % vs. 4.6 ± 1.9 %, P < 0.001) and HP1γ (12.0 ± 2.2 % vs.
2.8 ± 1.5 %, P < 0.001) compared with CNE-1-scramble
shRNA cells, while fewer CNE-2 SHP-1 overexpression
cells were positive for H3K9Me3 (2.6 ± 1.5 % vs. 9.6 ±
2.1 %, P < 0.001) and HP1γ (3.6 ± 1.5 % vs. 10.0 ± 2.3 %,
P = 0.001) (Fig. 3b). These results were confirmed by
western blot for H3K9Me3 and HP1γ, i.e. +292 % for
H3K9Me3 and +54 % for HP1γ in CNE-1 SHP-1
shRNA cells compared with CNE-1-scramble shRNA
cells, and −37 % for H3K9Me3 and −83 % for HP1γ in
CNE-2 SHP-1 overexpression cells compared with
CNE-2-empty vector cells (all P < 0.001) (Fig. 3c).
Effects of SHP-1 knockdown in CNE-1 cells and
overexpression in CNE-2 cells on NPC cell cycle distribution
As shown in Fig. 4a, compared with CNE-1-scramble
shRNA cells, CNE-1 SHP-1 shRNA cells had a higher
proportion of cells in G0/G1 (80.0 ± 1.7 % vs. 60.3 ±
Fig. 1 Alteration of SHP-1 expression in human nasopharyngeal carcinoma (NPC) cell lines CNE-1 and CNE-2 by lentivirus-mediated RNA interference
and overexpression, respectively. a SHP-1 protein expression in CNE-1 and CNE-2 cells was determined by western blot. b CNE-1 and CNE-2 cell survival
according to radiation dose determined by colony formation assay. *P < 0.05, **P < 0.01, ***P < 0.001 CNE-1 vs. CNE-2. CNE-1: non-transduced CNE-1
cells; CNE-1-scramble shRNA: CNE-1 cells transduced with lentivirus-mediated scramble shRNA; CNE-1 SHP-1 shRNA: CNE-1 cells transduced with
lentivirus-mediated SHP-1 shRNA; CNE-2: without transduced CNE-2 cells; CNE-2-empty vector: CNE-2 cells transduced with lentivirus vector; CNE-2
SHP-1 overexpression: CNE-2 cells transduced with lentivirus-mediated SHP-1 overexpression. According to fluorescence microscopy, transduction
efficiency in CNE-1 (c) and CNE-2 (d) cells was >90 % at 2 days after transduction (magnification: ×400). e SHP-1 mRNA expression were determined by
real-time RT-PCR. Relative mRNA expression was normalized to CNE-1 or CNE-2, and β-actin was used as an inner control. SHP-1 protein expression in
CNE-1 (f) and CNE-2 (g) cells was determined by western blot. β-actin was used as control. h Quantitative results of western blot are shown as mean ±
standard deviation (SD) from three independent experiments. **P < 0.01, ***P < 0.001 vs. CNE-1 or CNE-2; ##P < 0.01, ###P < 0.001 vs. CNE-1-scramble
shRNA or CNE-2-empty vector
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± 1.7 % vs. 25.0 ± 3.6 %, P < 0.001) and G2/M (6.0 ± 2.0 %
vs. 14.8 ± 4.5 %, P = 0.004) phases. Compared with CNE-2-
empty vector cells, CNE-2 SHP-1 overexpression cells had
lower proportions of cells in G1 (55.7 ± 2.6 % vs. 71.8 ±
2.9 %, P < 0.001) and G2/M (4.7 ± 0.8 % vs. 8.18 ± 1.3 %,
P < 0.001) phases, and a higher proportion of cells in S
phase (39.7 ± 2.2 % vs. 20.1 ± 2.9 %, P = 0.001).
The BrdU assay was used to monitor S-phase progres-
sion. Results showed that fewer cells were in the S phasein CNE-1 SHP-1 shRNA cells compared with CNE-1-
scramble shRNA cells (21.6 ± 4.7 vs. 67.8 ± 8.4 cells, P <
0.001), while more cells were in the S phase in CNE-2
SHP-1 overexpression cells compared with CNE-2-
empty vector cells (88.85 ± 5.6 vs. 38.6 ± 4.0 cells, P <
0.001) (Fig. 4b).
Compared with CNE-1-scramble shRNA cells, CNE-1
SHP-1 shRNA cells showed decreased expressions of
CDK4 (−44 %, P < 0.001), cyclin D1 (−41 %, P = 0.001)
and cyclin E (−97 %, P < 0.001). On the other hand,
Fig. 2 Effects of SHP-1 knockdown and overexpression on
radiosensitivity in CNE-1 and CNE-2 cells. After stable transduction
with lentivirus-mediated RNA interference and overexpression,
CNE-1 (a) and CNE-2 (b) cells were irradiated at different doses
(0, 2, 4, 6 and 8 Gy) (radiation absorption rate was 2 Gy/min). After
further incubation for 14 days, colony formation assays were used
to examine the radiosensitivity of the NPC cells. Survival curves
were fitted according to the multi-target single-hit model.
Compared with CNE-1 cells, cell survival was significantly different
(all P < 0.05, ANOVA) for all radiation doses in CNE-1 cells with
SHP-1 overexpression or silencing. Compared with CNE-2 cells,
cell survival was significantly different (all P < 0.05, ANOVA) for all
radiation doses in CNE-2 cells with SHP-1 overexpression or
silencing. *P < 0.05, **P < 0.01, ***P < 0.001 empty vector vs.
SHP-1-overexpression; ##P < 0.01, ###P < 0.001 scramble shRNA
vs. SHP-1-shRNA
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overexpression cells showed increased expression of
CDK4 (+41 %, P < 0.001), cyclin D1 (+90 %, P = 0.001),
and cyclin E (+124 %, P < 0.001) (Fig. 4c).
Effects of SHP-1 knockdown in CNE-1 cells and
overexpression in CNE-2 cells on p16/pRb pathway
in NPC cells
Compared with CNE-1-scramble shRNA cells, CNE-1
SHP-1 shRNA cells showed increased expression of p16(+120 %, P = 0.02), and decreased expressions of Rb
(−79 %, P < 0.001) and pRb (−76 %, P = 0.001). On the
other hand, compared with CNE-2-empty vector cells,
CNE-2 SHP-1 overexpression cells showed decreased ex-
pression of p16 (−95 %, P < 0.001), and increased expres-
sions of Rb (+358 %, P < 0.001) and pRb (+248 %, P <
0.001) (Fig. 5). Levels of p53 and p21 were unchanged in
both cell lines (all P > 0.05).
Discussion
The aim of the present study was to assess the role of
SHP-1 in the radioresistance and senescence of NPC cell
lines. Results showed that SHP-1 downregulation resulted
in increased senescence, increased radiosensitivity, higher
proportion of cells in G0/G1, decreased expression of
CDK4, cyclin D1, cyclin E, Rb, and pRb, and increased ex-
pression of p16. On the other hand, overexpression of
SHP-1 resulted in decreased senescence, decreased radio-
sensitivity, higher proportion of cells in S-phase, increased
expression of CDK4, cyclin D1, cyclin E, Rb, and pRb, and
decreased expression of p16.
SHP-1 has recently emerged as a useful diagnostic
marker and a potential target for therapeutic interven-
tion in several malignancies because of its functional in-
volvement in controlling cell proliferation and tumor
cell cycle distribution [29]. Several studies have reported
aberrant expression of SHP-1 in different cancers includ-
ing NPC [16, 15, 23, 14], but no functional study has yet
been reported in NPC. SHP-1 overexpression has been
reported in NPC and associated with a worse prognosis
[23]. Results of the present study showed that SHP-1 is
involved in the regulation of the cell cycle and cellular
senescence in NPC cells. In addition, SHP-1 levels were
higher at baseline in the CNE-1 cells compared with the
CNE-2 cells, and the CNE-1 cells showed higher radio-
resistance. This is supported by previous studies showing
that the CNE-2 cell line has been shown to be less radio-
resistant than CNE-1 [27], and that the DNA repair
mechanisms seem to be more efficient in the CNE-1 cell
line [27, 28]. The results of the present study suggest
that SHP-1 might play a role in radioresistance.
A previous study demonstrated that SHP-1 downregu-
lates p16 expression, which in turn interacts and stabilizes
FGFR1, thereby promoting epithelial-to-mesenchymal
transition and therefore aggressive metastatic behavior of
NPC cells [23]. Cellular senescence is an important mech-
anism for preventing the proliferation of potential cancer
cells [18, 19]. Cellular senescence critically depends on
two powerful tumor suppressor pathways: the p53 and
pRb/p16INK4a pathways [22, 21, 20]. Both pathways inte-
grate multiple aspects of cellular physiology to determine
and orchestrate cell fate. Senescence growth arrest usually
depends on the activation of the CDK inhibitors (p21CIP1
and p16INK4A) [30, 31], components of the tumor-






















SF2 0.75 0.78 0.78 0.82 0.56 0.62 0.60 0.61 0.74 0.55
D0 2.51 2.38 2.38 2.85 2.17 1.94 1.80 1.94 2.08 1.50
Dq 1.77 1.85 1.85 1.96 1.26 1.46 1.43 1.43 1.75 1.36
N 2.34 2.68 2.65 2.48 1.62 2.22 2.32 2.17 2.77 2.58
Note: SF2: cell survival fraction with 2 cGy irradiation dose; D0: mean lethal dose value; Dq: quasithreshold dose; N: extrapolation number
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generally associated with a G0/G1 cell cycle arrest. SAHF
formation coincides with the recruitment of heterochro-
matin proteins and Rb to E2F-responsive promoters and is
associated with the stable repression of E2F target genes
[32]. Notably, both SAHF formation and the silencing ofFig. 3 Effects of SHP-1 knockdown in CNE-1 cells and overexpression in CN
β-galactosidase staining (magnification: ×400). Arrows: senescent cells. Hete
expression were determined by immunofluorescence staining (b) (magnific
β-actin was used as an inner control. Data are shown as mean ± SD. **P < 0
CNE-1- scramble shRNA or CNE-2-empty vectorE2F target genes depend on the integrity of the Rb path-
way and do not occur in reversibly arrested cells [33].
Often lost in a variety of malignancies, p16 acts as an allo-
steric inhibitor of the CDK4/6 complex to prevent its
interaction with cyclin D1, inducing cell cycle arrest and
senescence by activating the Rb pathway [34]. The CDK4/E-2 cells on cell senescence. a Cell senescence was determined by
rochromatin markers H3K9Me3 and HP1γ location and protein
ation: ×400; red: Alexa Fluor® 568) and western blot (c), respectively.
.01, ***P < 0.001 vs. CNE-1 or CNE-2; ##P < 0.01, ###P < 0.001 vs.
Fig. 4 Effects of SHP-1 knockdown in CNE-1 cells and overexpression in CNE-2 cells on cell cycle distribution and cell cycle-related protein (CDK4,
Cyclin D1 and Cyclin E) expressions. a Cell cycle was determined by flow cytometry using propidium iodide staining three days after transduction.
b BrdU incorporation assay to monitor S phase progression (magnification: ×200). c Cell cycle-related protein expressions were determined by
western blot. β-actin was used as an inner control. Data are shown as mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001 vs. CNE-1 or CNE-2; ##P < 0.01,
###P < 0.001 vs. CNE-1- scramble shRNA or CNE-2-empty vector
Sun et al. Radiation Oncology  (2015) 10:152 Page 8 of 106-cyclin D1 complex-mediated phosphorylation and in-
activation of Rb allows the transcription of E2F-dependent
various cell cycle regulatory genes including cyclin E [34].
In the present study, stable suppression of SHP-1
mRNA in CNE-1 cells resulted in increased radiosensi-
tivity compared with the parental cells, a decrease in the
number of cells in S-phase and an increase in the
expression of p16. Furthermore, we observed that SHP-1
increased cell proliferation by modulating cell cycle
regulatory proteins like p16, CDK4 and cyclin D1. SHP-
1 silencing suppressed growth via a unique mechanisminvolving G0/G1 cell cycle arrest. Interestingly, SHP-1
silencing in NPC cells resulted in cellular senescence, as
suggested by cell morphology, increased SA-β-Gal-stained
cells, and SAHF formation, which are considered to be
characteristics of senescent cells [35]. Although the
involvement of p16 in cellular senescence and its
downregulation in NPC is well established [23], there is
still a lack of comprehensive studies about its role in NPC
senescence. Increased proliferation is mostly driven by
altered cell cycle progression. In the present study, down-
regulation of SHP-1 resulted in decreased proliferation
Fig. 5 Effects of SHP-1 knockdown in CNE-1 cells and overexpression in CNE-2 cells on senescence and cell cycle-related signaling molecules
(p16, Rb, p-Rb, p53, p21) expression. Protein expressions were determined by western blot. β-actin was used as control. Data are shown as mean
± SD. *P < 0.05, **P < 0.01, ***P < 0.001 vs. CNE-1 or CNE-2; #P < 0.05, ###P < 0.001 vs. CNE-1- scramble shRNA or CNE-2-empty vector
Sun et al. Radiation Oncology  (2015) 10:152 Page 9 of 10and G0/G1 cell cycle arrest, providing evidence that SHP-1
is a modulator of the cell cycle. Decreased proliferation and
cell cycle arrest was associated with downregulation of cell
cycle regulatory proteins such as CDK4 and cyclin D1.
However, modulation of SHP-1 expression had no effect on
expression levels of p53 and p21, two proteins that play im-
portant roles in cell cycle progression [36]. Cyclin E/D
downregulation might be a direct consequence of SHP-1
depletion, but further study is necessary to elucidate this
issue.
The present study is not without limitations. Indeed, we
could not investigate the PTEN/p27KIP1 pathway in the
present study. In addition, only cell lines were used, and
the observation of SHP-1 in actual tumors should bebeneficial. However, we plan to study this association in
the near future.
Conclusions
In conclusion, we observed that SHP-1 downregulation or
overexpression affected radioresistance, cell senescence
and cell cycle distribution in NPC cell lines. These findings
not only offer new perspectives in the modulation of sen-
escence by SHP-1, but also provide strong evidence for
SHP-1-based therapeutic interventions in NPC patients.
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